Haggerty K. 2010
Authors not listed · 2010
Complex biological responses require sophisticated analysis beyond simple biomarkers, a principle relevant to EMF health research.
Plain English Summary
This cancer research study investigated selumetinib, a drug that blocks MEK proteins involved in cell growth signaling. Researchers developed genetic signatures to predict which tumors would respond to this targeted therapy, finding that simple mutation tests weren't enough to determine treatment effectiveness. The work aims to improve personalized cancer treatment by better identifying patients likely to benefit from MEK inhibitor drugs.
Why This Matters
While this study focuses on cancer drug development rather than EMF exposure, it highlights a crucial principle that applies directly to EMF health research: biological responses can't be predicted by simple markers alone. Just as this cancer research shows that genetic mutations don't fully predict drug response, EMF health effects likely depend on complex interactions between exposure characteristics, individual biology, and cellular signaling pathways. The reality is that our bodies use intricate networks of molecular communication that can be disrupted in subtle ways. This research approach of looking at gene expression patterns and pathway interactions, rather than just single biomarkers, offers a more sophisticated framework for understanding how environmental exposures like EMF might affect human health. The science demonstrates that cellular responses to external influences are far more complex than we often assume.
Exposure Information
Specific exposure levels were not quantified in this study.
Show BibTeX
@article{haggerty_k_2010_ce4881,
author = {Unknown},
title = {Haggerty K. 2010},
year = {2010},
doi = {10.1158/0008-5472.CAN-09-1577},
}